Cwm LLC Grows Stock Position in Moderna, Inc. (NASDAQ:MRNA)

CWM LLC boosted its position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 27.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 118,335 shares of the company's stock after buying an additional 25,209 shares during the period. CWM LLC's holdings in Moderna were worth $11,768,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of MRNA. First Pacific Financial acquired a new stake in shares of Moderna in the 3rd quarter valued at approximately $27,000. Arlington Trust Co LLC raised its holdings in Moderna by 4,833.3% in the 4th quarter. Arlington Trust Co LLC now owns 296 shares of the company's stock valued at $29,000 after buying an additional 290 shares during the last quarter. GPS Wealth Strategies Group LLC raised its holdings in Moderna by 54.1% in the 3rd quarter. GPS Wealth Strategies Group LLC now owns 513 shares of the company's stock valued at $53,000 after buying an additional 180 shares during the last quarter. Archer Investment Corp raised its holdings in Moderna by 71.2% in the 3rd quarter. Archer Investment Corp now owns 534 shares of the company's stock valued at $55,000 after buying an additional 222 shares during the last quarter. Finally, Parkside Financial Bank & Trust raised its holdings in Moderna by 44.9% in the 3rd quarter. Parkside Financial Bank & Trust now owns 565 shares of the company's stock valued at $58,000 after buying an additional 175 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, President Stephen Hoge sold 2,388 shares of Moderna stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $225,833.16. Following the sale, the president now directly owns 1,515,898 shares in the company, valued at approximately $143,358,473.86. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, President Stephen Hoge sold 2,388 shares of Moderna stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $225,833.16. Following the sale, the president now directly owns 1,515,898 shares in the company, valued at approximately $143,358,473.86. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Noubar Afeyan sold 15,000 shares of Moderna stock in a transaction on Wednesday, April 17th. The stock was sold at an average price of $103.38, for a total value of $1,550,700.00. Following the sale, the director now owns 2,056,931 shares in the company, valued at $212,645,526.78. The disclosure for this sale can be found here. Insiders have sold 109,954 shares of company stock valued at $11,533,976 in the last three months. 15.20% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

MRNA has been the subject of a number of research reports. Jefferies Financial Group reiterated a "buy" rating and issued a $125.00 price objective on shares of Moderna in a report on Tuesday, April 9th. Oppenheimer upgraded shares of Moderna from a "market perform" rating to an "outperform" rating and set a $142.00 price objective for the company in a research note on Tuesday, January 2nd. William Blair reiterated a "market perform" rating on shares of Moderna in a research note on Monday, April 1st. Needham & Company LLC reiterated a "hold" rating on shares of Moderna in a research note on Thursday, April 11th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $125.00 price objective on shares of Moderna in a research note on Thursday, March 28th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $126.49.

Moderna Stock Up 3.0 %

MRNA traded up $3.05 during mid-day trading on Monday, reaching $104.46. 3,176,234 shares of the stock were exchanged, compared to its average volume of 4,148,157. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.36 and a current ratio of 3.42. The stock has a market capitalization of $40.00 billion, a PE ratio of -8.40 and a beta of 1.62. The company has a 50 day moving average price of $100.63 and a two-hundred day moving average price of $93.50. Moderna, Inc. has a 1 year low of $62.55 and a 1 year high of $142.79.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings data on Thursday, February 22nd. The company reported $0.55 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.78) by $1.33. The firm had revenue of $2.80 billion for the quarter, compared to the consensus estimate of $2.53 billion. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. The business's revenue for the quarter was down 44.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.61 EPS. As a group, research analysts anticipate that Moderna, Inc. will post -7.51 EPS for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.